Almirall joins project to allow study participants to use trial data
Project involves 27 partners including patient associations, hospitals and universities
Read More
Author: John Pinching
C4XD signs NRF2 Activator deal with AstraZeneca
C4XD will receive milestone payments worth up to $16m ahead of the first clinical trial
Read More
Bristol Myers Squibb immunotherapy-chemo combination gets NICE recommendation
Treatment involves adults with certain forms of advanced stomach and oesophageal cancer
Read More
Depressive therapy Spravato demonstrates superior efficacy
Research supports use of Spravato nasal spray in adults with major depressive disorder
Read More
Storm doses first patient with solid tumour drug candidate
Candidate is first molecule targeting an RNA methyltransferase enzyme to enter development
Read More- Myomaker Bio unveils lab‑grown human muscle platform to transform drug testing
- Survodutide delivers 16.6% weight loss in major phase 3 obesity trial
- Kahimmune Therapeutics signs collaboration agreement with Gustave Roussy
- BioDuro and CTI Biotechnology form partnership to accelerate preclinical drug development
- Asgard Therapeutics to present new preclinical data on AT‑108 at ASGCT 2026
